Capricor Therapeutics Q3 net loss widens as expenses rise
CAPR•Capricor Therapeutics reported no Q3 revenue and a net loss of $42.70 million, with operating expenses of $44.70 million. The company said cash resources are expected to fund operations for at least the next 12 months.
1. Quarterly results
Capricor Therapeutics reported no revenue in the third quarter of 2026 as it focused on late-stage therapy development. Net loss widened to $42.70 million, or $0.73 per share, and operating expenses rose to $44.70 million, mainly due to pre-commercial activities and manufacturing scale-up.
2. Outlook and spending
The company expects its cash resources to fund operations for at least the next 12 months. It plans to provide further financial guidance after regulatory clarity on Deramiocel; its outlook excludes potential product sales revenue and monetization of a Priority Review Voucher. Capricor reduced its workforce by about 10% in the quarter to reduce operating expenses and align resources with priorities.
